Table 1.
Nup88 Immunoreactivity of Tumors and Related Conditions
| Site and diagnosis | No. of cases and reaction | Extent of reaction* | Intensity of reaction† |
|---|---|---|---|
| Epithelial tumors | |||
| Stomach | |||
| Infiltrating adenocarcinoma | 11 /11 | 3+ /5+ | m/s |
| In situ carcinoma | 2 /2 | 3+ /4+ | m/s |
| Colon | |||
| Infiltrating adenocarcinoma | 12 /12 | 3+ /5+ | m/s |
| In situ adenocarcinoma | 3 /3 | 2+ /4+ | m |
| Villous adenoma | 3 /3 | 2+ /3+ | m |
| Tubular adenoma | 5 /5 | 2+ /3+ | w/m |
| Neuroendocrine carcinoma | 2 /2 | 3+ /4+ | m/s |
| Liver | |||
| Hepatocellular carcinoma | 4 /2 | 3+ /5+ | m/s |
| Dysplastic nodules | 2 /2 | 2+ /3+ | w |
| Pancreas | |||
| Adenocarcinoma | 7 /7 | 3+ /4+ | m/s |
| Neuroendocrine carcinoma | 3 /3 | 3+ /4+ | m/s |
| Breast | |||
| Infiltrating ductal carcinoma | 14 /14 | 3+ /5 | m/s |
| Infiltrating lobular carcinoma | 12 /12 | 3+ /5+ | m/s |
| In situ ductal carcinoma | 16 /16 | 3+ /4+ | m |
| In situ lobular carcinoma | 5 /5 | 3+ | m |
| Fibroadenoma | 2 /5 | 1+ | w |
| Fibrocystic disease | 16 /28 | 1+ /3+ | w/m |
| Lung | |||
| Squamous carcinoma | 8 /8 | 3+ /5+ | m/s |
| Adenocarcinoma | 12 /12 | 3+ /5+ | m/s |
| Bronchioloalveolar carcinoma | 2 /2 | 3+ /4+ | m |
| Large-cell carcinoma | 3 /3 | 3+ /5+ | m/s |
| Neuroendocrine carcinoma | 14 /14 | 3+ /5+ | m/s |
| Carcinoid | 9 /9 | 2+ /4+ | m |
| Hyperplastic bronchi | 3 /3 | 2+ /3+ | w/m |
| Ovary | |||
| Cystadenoma | 2 /3 | 2+ | w/m |
| Benign teratoma | 1 /1 | 2+ | w/m |
| Borderline serous carcinoma | 2 /2 | 2+ /3+ | m |
| Borderline mucinous carcinoma | 2 /2 | 2+ /3+ | m |
| Serous carcinoma | 6 /6 | 3+ /5+ | m/s |
| Mucinous carcinoma | 4 /4 | 3+ /5+ | m/s |
| Endometrioid carcinoma | 1 /1 | 4+ | m/s |
| Clear-cell carcinoma | 2 /2 | 3+ /5 | m/s |
| Uterus | |||
| Endometrial carcinoma | 12 /12 | 3+ /5+ | m/s |
| Endometrial hyperplasia | 4 /10 | 0 /2+ | w |
| Prostate | |||
| Adenocarcinoma | 11 /11 | 3+ /5+ | m/s |
| PIN, high grade | 6 /6 | 2+ /3+ | m/s |
| PIN, low grade | 2 /4 | 1+ /2+ | w/m |
| Benign glandular hyperplasia | 2 /6 | (+) /2+ | w/m |
| Kidney | |||
| Clear cell carcinoma | 4 /4 | 3+ /5+ | m/s |
| Adrenal | |||
| Cortical adenoma | 2 /2 | 2+ /3+ | w |
| Mesenchymal tumors | |||
| Fibrosarcoma | 5 /5 | 3+ /4+ | m |
| Malignant fibrous histiocytoma | 7 /7 | 3+ /4+ | w/m |
| Kaposi sarcoma | 2 /2 | 3+ /4+ | m |
| Dermatofibrosarcoma protuberans | 5 /5 | 3+ /4+ | m |
| Giant-cell tumor, benign | 0 /2 | 0 | — |
| Leiomyoma | 2 /2 | 3+ /4+ | w |
| Atypical fibroxanthoma | 2 /2 | 2+ /3+ | w |
| Angiolipoma | 1 /2 | (+) | w |
| Miscellaneous tumors | |||
| Large-cell lymphoma | 3 /3 | 3+ /4+ | m |
| Lymphoblastic lymphoma | 1 /1 | 3+ /4+ | m |
| Hodgkin’s disease | 4 /4 | 2+ /3+ | m |
| Malignant mesothelioma | 5 /5 | 3+ /5+ | m/s |
| Benign mesothelioma | 0 /2 | 0 | — |
| Glioblastoma multiforme | |||
| Malignant melanoma | 4 /4 | 3+ /5+ | m/s |
| Infiltrating | 4 /4 | 3+ /5+ | m/s |
| In situ | 2 /2 | 3+ /4+ | m/s |
*(+) = <1% positive cells: 1+ = 1–5% positive cells; 2+ = 6 to 15% positive cells; 3+ = 16 to 50% positive cells; 4+ = 51 to 95% positive cells; 5+ = 95% positive cells.
†S, strong; m, moderate; w, weak.